Certara, Inc. (NASDAQ:CERT) Shares Acquired by KBC Group NV

KBC Group NV lifted its holdings in Certara, Inc. (NASDAQ:CERT) by 64.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,998 shares of the company’s stock after purchasing an additional 3,125 shares during the quarter. KBC Group NV’s holdings in Certara were worth $85,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Blue Trust Inc. raised its stake in Certara by 112.3% in the third quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock valued at $46,000 after buying an additional 2,076 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Certara by 442.2% in the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after purchasing an additional 6,868 shares during the last quarter. Versor Investments LP acquired a new stake in Certara in the 3rd quarter worth approximately $162,000. Everence Capital Management Inc. boosted its stake in Certara by 21.0% in the 3rd quarter. Everence Capital Management Inc. now owns 14,910 shares of the company’s stock worth $175,000 after purchasing an additional 2,590 shares in the last quarter. Finally, 272 Capital LP purchased a new stake in Certara during the 3rd quarter worth approximately $177,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Stock Performance

NASDAQ CERT opened at $13.61 on Monday. Certara, Inc. has a 1 year low of $9.41 and a 1 year high of $19.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The company has a market capitalization of $2.19 billion, a PE ratio of -68.05, a P/E/G ratio of 9.33 and a beta of 1.57. The company has a fifty day moving average of $11.79 and a 200 day moving average of $11.72.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Barclays decreased their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Robert W. Baird reduced their target price on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Certara presently has an average rating of “Hold” and an average target price of $15.92.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.